CSI Market
Sign In | Register

Xeris Biopharma Holdings Inc (XERS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access XERS Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Xeris Biopharma Holdings Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-28.87
Depreciation & amortization0.66
Amortization of Other Assets7.22
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories8.65
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation15.21
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-30.78
Income Loss Attributable To Parent-
Accruedtradediscountsandrebates-
Gains Losses On Conversion Of Convertible Debt0.16
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable7.06
Increase (Decrease) in Accounts Payable4.54
Increase (Decrease) in Accrued Liabilities-3.01
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense4.34
Other Working Capital0.30
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities32.83
Discontinued operations0.00
Net Cash flow from Operating Activities18.13
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments to Acquire Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.53
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.53
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.38
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock7.93
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-17.21
Other net0.00
Payments for Initial Public Offering Costs-
Paymentsforpreferredstockissuancecosts-
Payments Of Debt Conversion Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-6.89
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow18.13
Total Cash Flow10.71
4 historic quarters locked

Sign in to unlock the full Xeris Biopharma Holdings Inc cash flow history.

Sign In Create Free Account

About Xeris Biopharma Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001867096-26-000065

Figures are derived from filed reports and may be restated. Historical data is subject to revision.